Analysis of prognostic marker expression in patients with metastatic ovarian cancer treated with platinum analogues and taxanes.

Postgraduate Thesis uoadl:2729759 451 Read counter

Unit:
Postgraduate Programme Biostatistics & Health Science Data
Library of the School of Health Sciences
Deposit date:
2018-04-02
Year:
2018
Author:
Skaltsi Tereza
Supervisors info:
Λάγιου Παγώνα, Καθηγήτρια , Ιατρική, ΕΚΠΑ
Γεωργούλιας Βασίλειος, Καθηγητής, Πανεπιστημίο Κρήτης
Χριστίνα Μπάμια, Αναπλ. Καθηγήτρια, Ιατρική, ΕΚΠΑ
Original Title:
Ανάλυση της έκφρασης προγνωστικών δεικτών σε ασθενείς με μεταστατικό καρκίνο των ωοθηκών υπό θεραπεία με ανάλογα της πλατίνας και ταξάνες. Μία κλινικό-εργαστηριακή μελέτη της Ελληνικής Ογκολογικής Ερευνητικής Ομάδας (ΕΟΕΟ)
Languages:
Greek
Translated title:
Analysis of prognostic marker expression in patients with metastatic ovarian cancer treated with platinum analogues and taxanes.
Summary:
Ovarian cancer is the tenth most common cancer and the fifth leading cause of cancer death in women in the Western world. The inability to predict the response of patients to specific treatments is a major obstacle in the improvement of the treatment of women with ovarian cancer. This happens because the decision of the chemotherapy remains empirical. Recently, molecular mechanisms of resistance to platinum and taxanes have been suggested, by expression of particular genes. These genes seem to influence the response of patients to chemotherapy. Nevertheless, there are still some unclear points, both on the display of the entire range of molecular interactions and on the harmonious relationship of the molecular mechanisms of resistance with clinical data.
The purpose of this analysis is to check the prognostic value of the ATP7B, ERCC1, BRCA1, Txr1, TSP1, Thioredoxin and DAXX genes which are involved in the resistance of the cancer cells to platinum and taxanes and to assess their importance in survival.
For this study, we used 146 samples from patients with ovarian cancer. These patients have been monitored at the Oncology departments of the University Hospital of Heraklion, Crete and the Elena Venizelos Hospital of Athens.
At first, the expression of the studied genes was calculated. Multivariate analysis was undertaken to highlight the importance of statistically significant factors regarding the response, time to disease progression and overall survival.
The time to relapse and the overall survival were estimated by the Kaplan-Meier method. For all tests the level of significance was defined as p = 0.05. The survival analysis indicated that patients with high mRNA expression level of BRCA1, TXR1 and TSP1 have longer median overall survival time (OS) compared with those patients with low levels of mRNA expression (58.0 months vs 39.0 months, p-value=0.043, 49.0 months vs 46.0 months, p-value=0.050, 50.0 months vs 39.0 months, p-value=0.044, respectively). The differences in expression levels of the remaining genes did not statistically significantly affect overall survival.
Main subject category:
Health Sciences
Keywords:
Ovarian cancer, Prognostic value, ATP7B, BRCA1, ERCC1
Index:
No
Number of index pages:
0
Contains images:
Yes
Number of references:
61
Number of pages:
39
File:
File access is restricted only to the intranet of UoA.

Tereza Skaltsi Master.pdf
1 MB
File access is restricted only to the intranet of UoA.